东瑞制药2023中期报告

Corporate Information2公司資料Group Structure4本集團架構圖Financial Highlights5財務摘要Management Discussion and Analysis6管理層討論及分析Other Information20其他資料Condensed Consolidated Statement of Profit or Loss28簡明綜合損益表Condensed Consolidated Statement of Comprehensive Income29簡明綜合全面收益表Condensed Consolidated Statement of Financial Position30簡明綜合財務狀況表Condensed Consolidated Statement of Changes in Equity32簡明綜合權益變動表Condensed Consolidated Statement of Cash Flows34簡明綜合現金流量表Notes to the Interim Financial Information38中期財務資料附註 BOARD OF DIRECTORS 董事會 EXECUTIVE DIRECTORSMs. LI Kei Ling(Chairman)Mr. HUNG Yung Lai 李其玲女士（主席）熊融禮先生 NON-EXECUTIVE DIRECTORMr. LEUNG Hong Man 梁康民先生 勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan CHIEF EXECUTIVE OFFICER 總裁 吳偉賢先生 Mr. WU Weixian 審核委員會 AUDIT COMMITTEE Mr. LO Tung Sing Tony(Chairman)Mr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 勞同聲先生（主席）EDE, Ronald Hao Xi先生林明儀女士 薪酬委員會 REMUNERATION COMMITTEE Mr. EDE, Ronald Hao Xi(Chairman)Ms. LI Kei LingMr. LO Tung Sing TonyMs. LAM Ming Yee Joan EDE, Ronald Hao Xi先生（主席）李其玲女士勞同聲先生林明儀女士 提名委員會 NOMINATION COMMITTEE Ms. LI Kei Ling(Chairman)Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan 李其玲女士（主席）勞同聲先生EDE, Ronald Hao Xi先生林明儀女士 核數師 AUDITORS Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor 安永會計師事務所執業會計師註冊公眾利益實體核數師 DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED東瑞製葯（控股）有限公司02 主要往來銀行 PRINCIPAL BANKERS 中國銀行（香港）有限公司，香港香港上海滙豐銀行有限公司，香港中國工商銀行蘇州市吳中支行中國農業銀行蘇州市南門支行中國銀行蘇州市吳中支行 Bank of China (Hong Kong) Limited, Hong KongThe Hongkong and Shanghai Banking Corporation Limited, Hong KongIndustrial and Commercial Bank of China Suzhou Wuzhong Sub-BranchAgricultural Bank of China Suzhou Nanmen Sub-BranchBank of China Suzhou Wuzhong Sub-Branch HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS 總辦事處及主要營業地點 香港灣仔軒尼詩道338號北海中心30樓3001–02室 Units 3001–02, 30/F, CNT Tower, 338 Hennessy Road,Wanchai, Hong Kong REGISTERED OFFICE 註冊辦事處 Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands 主要股份過戶登記處 PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111, Cayman Islands 香港股份過戶登記分處 HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 卓佳雅柏勤有限公司香港夏愨道16號遠東金融中心17樓 Tricor Abacus Limited17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong SHAREHOLDER’S CALENDAR 股東時間表 Closure of Register of Members for Interim DividendThursday, 21 September 2023 to Friday, 22 September 2023(both days inclusive) 二零二三年九月二十一日（星期四）至二零二三年九月二十二日（星期五）（首尾兩天包括在內） Record Date to determine Shareholder’s entitlement to theInterim DividendFriday, 22 September 2023 二零二三年九月二十二日（星期五） Interim Dividend, payableHK$0.015 per share, payable on or about 5 October 2023 每股港幣0.015元，約於二零二三年十月五日派發 03INTERIM REPORT 2023二零二三年中期報告 Group Structure As at 30 June 2023於二零二三年六月三十日 The board (the “Board”) of directors (the “Directors”) of DawnraysPharmaceutical (Holdings) Limited (the “Company”) is pleased to announcethe unaudited consolidated interim results of the Company and itssubsidiaries (collectively, the “Group”) for the six months ended 30 June2023 (the “period”) together with the comparative figures in 2022. Theseinterim results have been reviewed by the audit committee of theCompany. 東瑞製葯（控股）有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此提呈本公司及其附屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月（「本期間」）之未經審核綜合中期業績，連同二零二二年的比較數字。此等中期業績已經由本公司的審核委員會審閱。 Management Discussion and Analysis RESULTS 業績 本集團截至二零二三年六月三十日止六個月錄得收入 約 人 民 幣649,920,000元（ 二 零 二 二 年： 人 民 幣623,478,000元 ）， 與 二 零 二 二 年 同 期 比 較 約 增 加4.2%。母公司擁有人應佔溢利約人民幣255,941,000元（ 二 零 二 二 年： 人 民 幣171,661,000元 ）， 比 二 零二二年同期約增加49.1%。本期間溢利上升主要是由於處置蘇州東瑞製藥有限公司（「蘇州東瑞製藥」）天靈 路 廠 區 除 稅 後 政 府 拆 遷 補 償 款 約 人 民 幣115,984,000元 計 入 其 他 收 入（ 稅 前 人 民 幣142,882,000元）所致。撇除這非經常性項目，本期間溢利為人民幣139,957,000元，較去年同期人民幣171,661,000元 減 少 人 民 幣31,704,000元 下 跌18.5%，主要是受國家集採中標產品在長三角地區聯盟集採落標，加上新建研究院及蘭州東瑞製藥有限公司（「蘭州東瑞」）致使行政費用及研發費用有所增加所致。 The Group recorded revenue of approximately RMB649,920,000 for thesix months ended 30 June 2023 (2022: RMB623,478,000), representingan increase of approximately 4.2% as compared to the same period of2022. Profit attributable to owners of the parent was approximatelyRMB255,941,000 (2022: RMB171,661,000), representing an increase ofapproximately 49.1% compared to the same period of 2022. The increasein profit for the period was mainly due to the after tax governmentrelocation compensation amounting approximately RMB115,984,000 forthe disposal of assets at the factory of Suzhou Dawnrays PharmaceuticalCo., Ltd. (“Suzhou Dawnrays Pharmaceutical”) located on Tianling Roadincluded in other income (before tax RMB142,882,000). Excluding thisnon-recurring item,